Genetically engineered mouse (GEM) models are a pillar of functional cancer research. Here, we developed RapidCaP, a GEM modeling system that uses surgical injection for viral gene delivery to the prostate. We show that in Pten defi ciency, loss of p53 suffi ces to trigger metastasis to distant sites at greater than 50% penetrance by four months, consistent with results from human prostate cancer genome analysis. Live bioluminescence tracking showed that endogenous primary and metastatic disease responds to castration before developing lethal castration resistance. To our surprise, the resulting lesions showed no activation of Akt but activation of the Myc oncogene. Using RapidCaP, we fi nd that Myc drives local prostate metastasis and is critical for maintenance of metastasis, as shown by using the Brd4 inhibitor JQ1. Taken together, our data suggest that a "MYC-switch" away from AKT forms a critical and druggable event in PTEN -mutant prostate cancer metastasis and castration resistance.
INTRODUCTION
Prostate cancer is the most common malignancy in men and the second leading cause of cancer-related deaths in the Western world. As with other solid tumors, metastasis is the major cause of mortality and morbidity of patients, and since the discovery of androgen ablation therapy in the 1930s ( 1 ), lifeextending therapeutic options have only marginally changed ( 2 ) . The current breakthroughs in analysis of the prostate cancer genome have revealed that the gradual accumulation of genome alterations is intimately associated with metastatic disease progression, and the derived genome landscape revealed a critical role for copy-number changes (3) (4) (5) (6) . In the past, making sense of putative oncogenic events was made possible due to functional validation of candidate genes by mouse genetic engineering of prostate cancer (7) (8) (9) (10) (11) (12) (13) (14) (15) . Today , however, two major problems have arisen: fi rst, the genetically engineered mouse (GEM) models have not so far reconstituted highly penetrant metastatic prostate cancer. Second, the time associated with de novo generation of GEM models is far beyond today's speed of candidate gene discovery ( 16 ) . As a result, the use of prostate cancer GEM models has so far presented hardly any options for functional validation of genes that may form hallmarks of metastasis. As a corollary, the discovery of the biology and mechanisms of the reverse process, therapy for metastatic disease, has also eluded prostate cancer GEMs.
Today's ideal mouse model should thus combine highly penetrant metastatic disease progression, emergence of castration-resistant metastasis, simple visualization for therapy, and fully preserved architecture of naturally evolved lesions, which are embedded in their intact (micro)environment and immune system as judged by histologic analysis ( 17, 18 ) .
Although metastasis is indeed sometimes seen in postmortem analysis, the reported penetrance is too low for preclinical studies ( 19 ) . Furthermore, promoters that drive transgenes in the prostate are typically androgen dependent (e.g., the probasin promoter), thus making them incompatible with androgen deprivation therapy. Finally, a major drawback of classic genetic engineering lies in the time, cost, and effort needed for GEM generation. Projects carry typically a high risk as scientists become "locked in" with a few selected candidate gene alterations, the combination of which requires further lengthy breeding. Furthermore, state-of-the-art imaging systems such as ultrasound or MRI are expensive and require dedicated expert staff. The above major shortcomings of prostate cancer GEMs have unfortunately put them out of sync with today's speed of human cancer genome analysis and the resulting need for fast validation of candidate cancer genes ( 20 ) . As a consequence, animal modelers of cancer are actively exploring new approaches ( 16 ) .
Here, we developed a new mouse model that is designed for metastatic prostate cancer analysis and therapy, termed RapidCaP. Using a surgical process to deliver viral transgenes into the prostate, we are able to achieve tissue-specifi c single or multiple gene alternations, such as knockout and overexpression, without the need for cross-breeding of animals that harbor multiple engineered alleles. Inclusion of a luciferase marker with target genes enables live monitoring of metastasis, therapy-induced regression, and relapse. Histologic analysis reveals new biology of metastasis and delivers lead candidate genes, which can be functionally validated using the RapidCaP system. Stable transgene delivery to epithelial prostate cells by virus injection. A, the RapidCaP system. 1, design and production of lentivirus harboring candidate cancer genes and marker genes. 2, surgical injection of virus directly into anterior prostate gland. 3, noninvasive bioluminescence imaging to monitor disease progression and therapeutic effects. Note that adenovirus is depicted for purely aesthetic reasons. B, live imaging of LV-Luciinjected Bl6 mice and noninjected control 60 days after injection suggests persistent transgene expression. C, post-mortem autopsy imaging of LV-Luci and noninjected control mice 98 days after injection. The genitourinary (GU) tract comprises bladder (B), seminal vesicle (SV), and anterior prostate (AP). The luminescence signal is found in the (injected) right anterior prostate lobe and also in the seminal vesicle. Note that fl uorescence-activated cell sorting (FACS) experiments fail to identify infected (tomato-FP) seminal vesicle cells, potentially suggesting that the seminal vesicle signal is extracellular. PCR of prostate genomic DNA reveals the luciferase transgene (300 bp) only in the LV-Luci-injected prostate lobe. D, anti-luciferase immunofl uorescence on LV-Luci-injected and noninjected control prostate reveals luciferase expression in prostate luminal epithelium. Scale bar, 47 μm. E, hematoxylin and eosin (H&E) staining of LV-Luci-injected and noninjected control prostate reveals retention of normal glandular architecture. Scale bar, 100 μm. As shown, this approach allowed successful monitoring of mice with injected prostate by live imaging ( Fig. 1B ) , and postmortem analysis ( Fig. 1C ) 60 days after injection revealed a luciferase signal only in the injected anterior prostate and adjacent seminal vesicle (see below for the discussion of the seminal vesicle signal; Fig. 2A ). PCR analysis revealed the presence of the luciferase transgene in the animal with injected anterior prostate ( Fig. 1C , bottom right) , whereas immunofl uorescencebased histology using anti-luciferase antibodies revealed expression of luciferase in the prostatic epithelium. Although infection of nonepithelial cells can by no means be excluded, the epithelial immunofl uorescence signal typically clearly dominated over the stromal signal (Supplementary Fig. S1A ; see also Fig. 1D ). On the basis of the fl uorescence-activated cell sorting (FACS) analysis with fl uorescent marker transgenes, our technique infects some 0.3% of the approximately 100 million anterior prostate cells (not shown). Histologic comparison of injected and noninjected glands revealed no morphologic alterations in the injected glands, and immunohistochemistry (IHC) analysis of the PTEN pathway and the Ki-67 proliferation marker did not reveal any anomalies ( Fig. 1E and Supplementary Fig. S1B ). Successfully injected/ infected prostates stained negative for the CD3 T-cell marker, and no signs of infl ammatory responses were observed (Supplementary Fig. S1C , top and middle). These results demonstrated that viral transgene delivery and stable integration into genomic DNA in the anterior prostate epithelium is feasible with our technique.
Transgenes and markers

Post
Prostate-Specifi c Delivery of Cre Recombinase Results in Focal Pten / Trp53 -Defi cient Disease
Analysis of mouse models of prostate cancer revealed that loss of Trp53 function is a critical step for disease progression in Pten pathway-mutant animals ( 21, 22 ) . Thus, we next injected lentiviral Cre-luciferase double-transgenic virus (LVCre/Luci) into the prostates of Pten loxp/loxp ; Trp53 loxp/loxp mice. As shown in Fig. 2A , LV-Cre/Luci-injected mice typically show a strong luciferase signal in the genitourinary region. Post-mortem analysis (69 days after injection) revealed that the injected anterior prostate and associated seminal vesicle are the luminescence source-discussed below. In contrast, 62% of lentiviral luciferase (LV-Luci) virus-injected mice demonstrated loss of signal within 78 days (not shown). PCR analysis of genomic DNA from anterior prostate revealed recombination of the tumor suppressors, Pten and Trp53 , specifi cally in the LV-Cre/Luci-injected right anterior prostate ( Fig. 2B , Δ Pten , Δ p53 ). Strikingly , anterior prostate IHC analysis (see Fig. 2C ) revealed the highly focal nature of disease initiation in this model; only a small region within one gland showed increased proliferation (Ki-67), loss of Pten, and strong Akt activation, whereas the vast majority of glands in the prostate retained completely normal morphology and staining for these proteins ( Fig. 2C , right, pAkt, Pten). Note that increased proliferation and cell expansion were not seen in stromal cells. Indeed , after histopathologic analysis of more than 60 prostate-injected cases, the only cell type in which we observed expansion was epithelial prostate cells. Furthermore, we again observed no immunogenicity of the viral injection procedure as shown by CD3 staining (see Supplementary Fig. S1C ). These data demonstrated that the RapidCaP system triggered focal disease initiation, which is thought to be a feature of the human disease-initiation process. Note that, in contrast, the probasin-driven Cre conditional knockout (cKO) systems of Pten and Trp53 or Smad4 delete their target genes in every cell of the prostate epithelium, which results in massive expansion of prostate size to several centimeters in diameter ( 22 , 23 ) and is accompanied by a nonepithelial sarcoma phenotype (19) .
Deletion of Pten and Trp53 Triggers Disease Dissemination
Analysis of the human prostate cancer genome has revealed that PTEN and TP53 are codeleted in half of all metastatic samples ( 3 , 21 ) . In mice, however, the complete Pten and Trp53 deletion in the prostate resulted in massive and lethal tumor growth ( 22, 23 ) . To investigate disease progression in the above RapidCaP system (LV-Cre/Luci injection into Pten loxp/loxp
; Trp53
loxp/loxp prostate), mice were imaged for a period of several months. As shown in Fig. 3A , the luminescence signal was initially observed in the lower abdominal region (up to 25 days after injection). Later, however, strong signal spread was detected in the upper body and midbody (72-140 days after injection). Typically, the signal fi rst disseminated to below the neck and later to the mid-abdomen, as shown. Quantifi cation of whole-body, primary and secondary signals ( Fig. 3B ) revealed how they both increased over time. Most importantly, no spreading of the luminescence signal was observed in any of the control injection cohorts (see Fig. 3C ). As mentioned above, 62%, or 18 of 29 non-genemodifying control-injected mice, instead showed a decrease of the primary luciferase signal over time (see Supplementary  Fig. S2 for typical examples of a RapidCaP time course). Overall (see Fig. 3C ), 50% of animals showed disease dissemination 4 months after injection. In post-mortem analysis, secondary signals were confi rmed in lymph nodes (mediastinal, lumbar, and caudal), spleen, liver (shown in Fig. 3D ), pancreas, and lung. Organs near the genitourinary tract (excluding bladder) were also often signal-positive. Importantly, LV-Cre/ Luci-injected prostate was macroscopically indistinguishable from noninjected prostate ( Fig. 3D , ni vs. inj), revealing a stark contrast to the probasin-Cre -driven Pten/Trp53 cKO model. To date, after analysis of more than 300 injected animals, those without gene alteration never showed luciferase signal spread in post-mortem analysis. Note that the seminal vesicle on the side of the injected prostate was invariably luminescencepositive from the day of injection, also in luciferase-only control injections. This argues against positive biologic selection, and in agreement, we never found phenotypic changes by IHC analysis of seminal vesicles (not shown). In fact, seminal vesicles have never shown any phenotypes in the many whole-body knockout models driven by heterozygosity of Pten ( 11 , 15 , 21 ) . Recombination of Pten and Trp53 in the signal-positive secondary organ sites was confi rmed by PCR ( Fig. 3E ) . Histopathologic examination of prostates revealed focal invasion as shown by the frequent focal budding of epithelial cells ( Fig. 3F ). 
RESEARCH ARTICLE
;Trp53
loxP/loxP prostate reveals a focal lesion in the luminal epithelium of one gland (H&E), which also displays increased proliferation, specifi c to epithelial cells (Ki-67). Loss of Pten expression, activation of Akt (pAkt), and increased proliferation are also found in this region (middle), which is a unique focus of disease in the cross-section of the entire anterior prostate (right). Note that surrounding stroma remains unaffected in all panels. Scale bars, 100 μm (top right) and 50 μm (all other panels). GU, genitourinary. analysis was performed on the animal shown in Fig. 4A . First, we defi ned markers for mutant cancer cells by analyzing the prostate. As expected, focal regions in the prostate lost Pten expression ( Fig. 4B ). In addition, the epithelial markers cytokeratin-8 (Ck8) and androgen receptor (Ar) were absent specifi cally in regions where Pten (and p53) was no longer expressed ( Fig. 4B , arrows), which is in full agreement with previous results ( 24 ) , and in contrast to normal prostate ( Supplementary Fig. S3C , left). On inspecting the lungs of this animal ( Figure 4 . Histogenic analysis confi rms prostate cancer metastasis to lung. A, autopsy imaging of the mock-castrated RapidCaP mouse (#3) reveals disease dissemination to lung, lymph nodes, spleen, and liver at the trial endpoint (10 months after injection). B, identifi cation of histogenic markers that defi ne prostate cancer cells by IHC analysis of prostate in animal from A: Pten and Ck8 (black arrows, see black arrowheads for region with normal protein levels) and Pten and AR (red arrows, see red arrowheads for the region with normal protein levels). Note that "loss" of AR staining is a hallmark of Pten / p53 -null prostate (see the text). Scale bar, 100 μm. C and D, IHC analysis of lung from above mouse reveals metastatic nodules that are Pten-, Ck8-, and AR-negative and positive for the prostate epithelial marker Nkx3.1. Boxes, areas of magnifi cation. Scale bars, 100 μm (top and bottom left) and 50 μm (all other panels). E, double immunofl uorescence (IF) labeling confi rms double negativity for Pten and Ck8 in a metastatic lung nodule (nod) shown in C and D (yellow circles and arrowheads). Note that, in contrast, colabeling of Pten and Ck8 in adjacent normal lung epithelia (nl, white dashed circles and arrowheads) shows double-positive staining. Scale bar, 50 μm. F, anti-luciferase antibody staining and immunofl uorescence analysis of lung from C to F confi rms that metastatic nodules are luciferase-positive (white arrows) and Pten/Ck8-defi cient (red arrowheads). Scale bar, 100 μm. The nodules were composed of proliferating atypical cells with large, pleomorphic, hyperchromatic nuclei and scantto-moderate amounts of amphophilic cytoplasm. These cells were immunohistochemically characterized by loss of Pten as well as loss of Ck8 and Ar, thus matching the features of the mutant prostate epithelial cells. The metastatic nodules showed focal, faint positivity for the prostatic differentiation marker Nkx3.1, further supporting prostatic origin. The loss of the low-molecular-weight Ck8 was particularly informative because the normal alveolar and bronchiolar lung epithelium displayed high expression of this cytokeratin (see also Supplementary Fig. S3C, right) , whereas the metastatic nodules stood out as negative mutant epithelial islands. To confi rm that the metastatic cells were truly double-negative for Pten and Ck8, double immunofl uorescence labeling was performed on lung sections. Indeed (see Fig. 4E ), metastatic nodules in the lung (nod) were negative for both Pten and Ck8 (yellow circles and arrowheads), whereas normal bronchiolar epithelium (nl) showed high expression of both proteins (white, dashed circles and arrowheads). Next, we used anti-luciferase immunofl uorescence to further study the metastatic nodules. Only injected prostate was stained, thus establishing our positive control for the procedure (Supplementary Fig. S3A ). As shown in Supplementary Fig. S3B , lungs with metastatic nodules [hematoxylin and eosin (H&E)] showed readily detectable luciferin-positive cells and nodules (see Luci). These sites corresponded to tumor sites with loss of Pten and Ck8 staining, as shown in Fig. 4F . Importantly, Ki-67 IHC analysis revealed that metastatic nodules contained cells with a high proliferation rate ( Supplementary Fig. S3D ). We next confi rmed that levels of the androgen-driven Nkx3.1 protein were high in prostate, the lung metastatic nodules, but markedly reduced in the castration-resistant prostate cancer (CRPC; Supplementary Fig. S3E ), thus inversely correlating with the expression levels of Myc, as published previously ( 25 ) . Additional cases of lung metastasis confi rming the immunohistologic correlations are shown in Supplementary  Fig. S4 . Taken together, our results are consistent with extensive prostate cancer metastasis to lung in RapidCaP.
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Pten / Trp53 -Defi cient RapidCaP Metastasis Responds to Castration
Androgen ablation therapy is the standard of care for advanced prostate cancer, causing widespread atrophy of prostate cells and the derived metastases. Surgical castration was conducted on mice with secondary signals, and bioluminescence imaging was continued once per week on a total of 16 animals as summarized in Supplementary Fig. S5A -S5C: 7 castrated Pten/Trp53 -mutant RapidCaP animals, 7 mockcastrated Pten/Trp53 -mutant RapidCaP animals, and 2 castrated LV-Luci prostate-injected normal controls. Figure 5 illustrates the typical results obtained from a group of 5 trials ( Fig. 5A and B ) , consisting of 2 castrated animals ( Fig. 5A , cast-1, cast-2; Fig. 5B , #4, #5), 2 noncastrated controls ( Fig. 5B , #2 , #3), one of which underwent a mock castration surgery (#3), and a nontreated wild-type (wt) mouse (#1). The castrated animals showed partial (cast-1) or complete (cast-2) therapy response within 7 weeks after castration and, importantly, both the primary and secondary signals regressed ( Fig. 5A ,  7 weeks; see also Supplementary Fig. S5A, graph) . However, regression was followed by aggressive relapse of both primary and secondary signals, now growing much more rapidly than before castration (see Fig. 5A , 7-27 weeks; Supplementary  Fig. S5A ), a hallmark of human castration resistance. In contrast (see Fig. 5B and Supplementary Fig. S5B ), both control animals showed steadily increasing signal intensity. Quantifi cation ( Fig. 5C and Supplementary Fig. S5C ) confi rmed this sharp increase in intensity for both primary and secondary disease. This resulted in a typical "hockey stick" growth behavior (compare precastration with postcastration growth) just before these animals needed to be sacrifi ced to prevent excessive tumor burden. Clear signs of morbidity, such as palpable tumors, low activity, hunched backs, and a rough hair coat, were observed in these animals. Figure 5D shows the quantitative analysis of regression and relapse and breakdown of the data into primary and secondary disease. This analysis revealed the kinetics of how prostate and metastatic signals in both animals responded to castration. Post-mortem analysis of animal #4, from Fig. 5B , illustrates the typical metastasis to organs including lymph nodes, liver, spleen, and pancreas (some of which were palpable). The prostate itself was massively enlarged, spanning close to 3 cm in diameter, in stark contrast to the 5-to 7-mm diameter of noncastrated Pten / Trp53 -defi cient RapidCaP prostate ( Fig. 6A and B , bottom; see also Supplementary Fig. S6, slide overviews) .
Taken together, the castration experiments confi rmed that RapidCaP mice developed prostate metastatic disease, which initially responds to androgen deprivation and eventually relapses to develop CRPC. It is likely that residual disease after castration, as shown in the Cast-1 animal ( Fig. 5A , Cast-1, 7 week), is due to preexisting AR-low/negative cells such as the ones shown in Fig. 4B and D , which could expand upon castration to form AR-negative CRPC tumors (see Fig. 6C ). To study the molecular makeup of castration-resistant disease, we turned to IHC analysis.
Myc Expression Can Drive Metastasis in the Absence of Akt Activation
IHC analysis of the relapsed prostate tumor (see Fig. 6C and Supplementary Fig. S6 ) confi rmed the consistent emergence of anaplastic cells with loss/background levels of Pten, Ar, and Ck8, consistent with mutant prostate of noncastrated mice (shown in Fig. 4B-F ) . However, Akt was not activated despite Pten loss ( Fig. 6C and Supplementary  Fig. S6C, right) . We then analyzed components of the phosphoinositide 3-kinase (PI3K) pathway to understand whether feedback mechanisms ( 26, 27 ) or parallel Pdk1 kinase activation ( 28 ) was suppressing pAkt. As shown ( Fig. 6D ) , Pdk1 was not phosphorylated in the castration-resistant tumor, in which pAkt levels were low. Furthermore, we found even lower ribosomal protein S6 phosphorylation after castration than in wt prostate (see also Supplementary Fig. S7C for IHC analysis of phospho-S6). These results suggested that PI3K signaling is low in metastasis and after castration. Instead, strong Myc staining was seen in both nuclei and cytoplasm throughout the tumor mass ( Fig. 6C and Supplementary  Fig. S6 Fig. 4A ) shows metastasis to distant organs and massive prostate enlargement. B, castration results in prostate epithelium atrophy and diffuse cytoplasmic AR staining (top). Note that Pten / Trp53 loss in RapidCaP does not cause a signifi cant increase in prostate size (bottom). Scale bar, 100 μm. C, IHC analysis of Cast-1 prostate shows loss of Akt activation, lost/low cytokeratin epithelial and basal cell markers Ck8 and CK5, respectively. In contrast, there is strong activation of Myc in tumor cells in the therapy-resistant prostate tumor. Scale bars, 1 mm (Myc overview) and 50 μm (all other panels). D, Western blot analysis of PI3K reveals no feedback (pS6) or parallel pathway (pPdk1) activation of castration-resistant tumor shown in C. E, a strong increase in Myc mRNA expression is detected in the castration-resistant tumor from C. Error bars, SD; ***, P = 0.0001. F, FISH analysis reveals Myc gene amplifi cation in disease progression from prostate to lung metastasis of the same animal. Myc gene amplifi cation is also observed in a CRPC. The percentage of nuclei with >2 copies is indicated; scale bar, 5 μm. LN, lymph nodes; qPCR, quantitative PCR; Lt, left. 
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and exclusively nuclear Myc ( Supplementary Fig. S3F ), similar to normal prostate (not shown). Myc RNA expression sharply increased in castration-resistant cancer ( Fig. 6E ) , and by using FISH analysis ( Fig. 6F ) , we found that the Myc gene was amplifi ed in 32% of CRPC nuclei. We also observed Myc amplifi cation in metastasis (21% frequency), whereas the corresponding primary prostate showed no gene amplifi cation. These data suggested that Myc and not phospho-Akt (pAkt) may be driving metastasis and castration-resistant cancer, in contrast to disease initiation, where we observed strong Akt activation (see pAkt; Fig. 2C ). We frequently saw mixed prostate glands with pAkt high and low staining regions ( Supplementary Fig. S7A ), which also showed low pS6 and Ck8 staining but were positive for Myc and AR. These fi ndings suggest that the low pAkt phenotype fi rst emerges in the prostate and is selected for during metastasis and castration resistance, along with partial amplifi cation of the gene and strongly increased transcription.
Next, we made full use of the RapidCaP system for the discovery and validation of a metastasis driver gene. First, we studied Akt and Myc status in prostate metastasis to lung. As shown ( Fig. 7A ), metastasis to lung in the mock-castrated animal showed absence of Akt activation but high Myc levels in cytoplasm and nuclei of all metastatic nodules. This situation was comparable to the IHC staining observed in the castrated animal prostate ( Fig. 6C ), but very different from the mock-castrated animal's own prostate (see Supplementary  Fig. S3F ). Therefore, our results suggested that increased and/or mislocalized Myc may contribute specifi cally to the metastatic process (see Discussion). To test this hypothesis, we generated a cohort of Myc -driven RapidCaP mice.
A retroviral construct harboring Myc and luciferase was used (see Supplementary Fig. S7B and Methods) and validated in vitro before injecting into mice (not shown). Two animal geno types were selected for injection: Pten hy /+ (" Pten hyper") mice with 25% reduced Pten levels ( 11 ) , to test whether Myc cooperates with activation of Akt in driving metastasis, and WT mice, to test whether Myc can drive metastasis on its own. As shown in Fig. 7B (top) , Pten hy /+ mice with Myc -luciferase retrovirus (RV-Myc-Luci)-injected prostates retained their luminescence signals until they were sacrifi ced for analysis, and so did the WT mice (not shown). There were, however, no signals detected in live imaging beyond the lower abdominal region in both genotypes, suggesting that no strong dissemination to distant organs had occurred. Typical post-mortem imaging ( Fig. 7C and Supplementary Fig. S7C , 54 days after injection) revealed luciferase positivity of the injected (right) anterior prostate lobes in both genotypes (yellow arrows), and Myc overexpression was confi rmed by quantitative reverse transcription PCR (qRT-PCR ; Supplementary Fig. S7D ). Importantly, post-mortem visualization revealed that the majority of Myc-virus-injected animals had secondary signals (green arrows). These were limited to organs close to prostate, such as local lymph nodes and epididymal fat pads, confi rming the lack of distant dissemination observed in live imaging. Statistical cohort analysis ( Fig. 7B , bottom) showed signifi cant frequencies of local disease dissemination in both the Ptenmutant and WT mice, even if a signifi cant increase in local metastasis was observed in the mutant cohort. Thus, Myc overexpression suffi ces to induce local metastasis in normal prostate, but the process can be accelerated through even only modest suppression of Pten .
Finally, to probe whether Myc was needed to drive growth or maintenance of the metastatic cells, we used the Mycsuppressing Brd4 inhibitor JQ1 ( 29-31 ) on mice with established Pten/Trp53 -deleted metastases. We confi rmed that JQ1 administration (daily at 50 mg/kg) suppressed Myc transcription in prostate tissues already after 4 days ( Supplementary  Fig. S8 ). As shown ( Fig. 7D ) , JQ1 inhibited growth of metastatic cells within 17 days and had little effect on primary disease signal (quantifi ed in Fig. 7E ). Taken together, our data suggest that the spontaneously increased Myc expression observed in metastasis or castration resistance is a key driver and a potential drug target against Pten -mutant metastasis.
DISCUSSION
Virus-based in vivo gene transfer has been used to study various cancer types ( 32, 33 ) . The RapidCaP system presents us with new technology for the exploration of metastatic prostate cancer and its therapy. This approach has delivered two unexpected results: First, we showed that deletion of the Pten and Trp53 tumor suppressors suffi ces to trigger metastatic prostate cancer at high penetrance within a few months. Second, Pten/Trp53 -defi cient metastasis shows no Akt activation, but rather Myc activation instead.
The fi rst result validates our previous analysis of mouse genetics and human prostate cancer genomes, where we found that p53 is a gatekeeper for metastatic progression of PTENmutant prostate cancer ( 21 ) . The result is corroborated by our fi nding that p53 is haplosuffi cient for preventing distant metastasis, as Pten loxP/loxP
; Trp53
+/loxP RapidCaP mice do not present metastases (not shown). These fi ndings are in line with a critical role of the p53-mediated senescence response after Pten loss ( 22 , 34 , 35 ) and its potential in preventing metastatic prostate cancer ( 36 ) . These results could not readily be obtained with the classic Pten -mutant GEMMs where metastatic disease is not, or only rarely, observed, as primary prostate cancers grow to lethal size ( 22, 23 ) . In patients, this genetic setting occurs in more than half of the recently analyzed metastatic cancer genomes ( 3 , 37 , 38 ) .
The second result demonstrates the utility of the RapidCaP approach, which allows for identifi cation and fast validation of metastasis mechanisms. The loss of Akt activation in Pten -defi cient metastatic disease and castration-resistant tumors is unexpected. This could suggest that these tissues no longer respond to PI3K pathway inhibition, despite Pten loss, a hypothesis that can be tested using RapidCaP. The metastatic Pten/Trp53 -mutant disease shows clearly less pAkt signal than the primary disease-initiating counterpart (compare Fig. 6C , right, and Fig. 2C , right) . Although the mechanism of pAkt suppression remains to be determined, it is apparent that Myc is overexpressed in this setting, suggesting the existence of a Myc switch in Pten -mutant metastatic disease progression. Intriguingly, in this setting, Myc is also strongly expressed in the cytoplasm, in contrast to the nuclear, weak Myc expression in normal prostate. Recently, a cytoplasmic cleavage product of Myc, termed Myc-Nick, has been shown to control muscle cell differentiation ( 39 ) . Thus, it will be interesting to see if MycNick is present in the metastatic or castration-resistant lesion. 
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loxP/loxP mice reveals absence of pAkt activation. In contrast, Myc levels are strongly increased, especially in the cytoplasm (compared with prostate; Supplementary Fig. S3F ). Note the apparent further Myc increase in castration-resistant disease ( Fig. 6C ) compared with this mock-castrated metastasis. Scale bar, 50 μm. B, top, typical live imaging of RV-Myc -Luci-injected Pten hy/+ mice shows lower abdominal signals and absence of distant metastasis (in contrast to LV-Cre/Luci-injected Pten loxP/loxP ;Trp53 loxP/loxP mice; Fig. 3A ). Note that Pten hy/+ mice express only 75% Pten throughout their body. Bottom, Kaplan-Meier analysis of disease spread in indicated RapidCaP models reveals that Myc expression can drive local dissemination of prostate cancer and cooperate with Pten suppression. Log-rank (Mantel-Cox) testing shows that wt, Pten hy/+ , as well as negative control study arms, are signifi cantly different ( P = 0.004). C, autopsy analysis of RV-Myc-Luci-injected mice reveals local, mostly lower abdominal disease dissemination from prostate (yellow arrows) to secondary sites (green arrows), including local lymph nodes. Also see Supplementary  Fig. S7C. D 
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The MYC gene is frequently amplifi ed, especially in metastatic human prostate cancer, as part of the signature chromosome 8p amplifi cation ( 3 ) and has previously been functionally validated as a driver of prostate cancer ( 14 , 40 ) . It is known to cooperate with PI3K pathway activation in mouse models of mainly primary disease ( 41, 42 ; reviewed in ref. 40 ) . The nonepithelial (Ck8-defi cient) histology of Pten/Trp53 -mutant metastasis remains to be validated in PTEN / TP53 -mutant human prostate cancer, which represents between 54% and 65% of metastatic prostate cancer cases ( 3 , 37 , 38 ) . The RapidCaP system, however, revealed a specifi c role for Myc as a druggable driver of Pten -mutant metastasis. These results suggest that a quantitative and qualitative change in Myc expression succeeds Akt activation in driving prostate metastasis. Furthermore, we have seen that Pten / Trp53 -mutant metastasis is still androgen-dependent, and that disease relapse is characterized by the absence of pAkt and high Myc levels. It remains to be determined whether and how Myc function suppresses Akt activity and how these two cancer pathways can best be targeted coordinately to prevent disease relapse.
Thanks to its versatility, accelerated time frame, and amenability to genome sequencing, the RapidCaP system is very well positioned to explore these questions, and thus may help end death and suffering from today's incurable prostate cancer. , primer 1 (5′-CACAAAAACAGGTTAAACCCAG-3′) and primer 2 (5′-AGCACATAGGAGGCAGAGA C-3′) were used.
METHODS
Mice
Viral Constructs
Lentiviral constructs-the Luc.Cre lentiviral plasmid (Tyler Jacks, Addgene plasmid 20905), pMD2.G, and psPAX2-were purchased. The luciferase lentiviral plasmid was generated by eliminating CreNLS from the above construct. The retroviral Myc-luciferase construct was a kind gift from Dr. Scott W. Lowe (Memorial Sloan-Kettering Cancer Center).
Retrovirus Productions and Infections
Retrovirus was produced by calcium phosphate transfection; 6 × 10 6 phoenix cells were plated in 10-cm plates 6 to 12 hours before transfection with 15 μg of target construct and 5 μg of ecotropic helper plasmid. Fresh media was added 12 hours after transfection and viral supernatant was collected four times, 24, 36, 48, and 60 hours after transfection. Viral supernatant was fi ltered through a 0.45-μm fi lter, then concentrated by ultracentrifugation (2 hours at 20,000 × g). Before the viral injection to prostate, an in vitro infection test for each batch of viruses was conducted.
Lentivirus Productions, Infections, and Injections
Lentiviruses were produced by calcium phosphate transfection. 293FT cells were plated for transfection density 8 × 10 6 cells per 
Cell Lines
293FT and ecotropic Phoenix cells were a kind gift from Dr. Scott W. Lowe. They were authenticated for propagation of lentivirus and retrovirus, respectively.
Intraprostate Injection
After exposure to anesthesia (isofl urane, 2%), the lower half of the abdomen was shaved and the mouse was placed in a surgery hood. The mouse was constantly exposed to isofl urane via a nose cone for the entire duration of the 10-minute surgery. The shaved region was cleaned with betadine, followed by sterile PBS three times. A 0.5-inch incision in both the skin and peritoneum was made along the lower abdominal midline to allow the right anterior prostate to be positioned for injection on a sterile support. Typically, 30 μL of concentrated virus was injected into the right anterior prostate. The incision was then sutured and the skin was stapled shut using two to three stainless steel EZ Clip wound closures. After animals were observed for complete recovery from anesthesia, they were warmed under a heating lamp to regain the ability to maintain sternal recumbence and given DietGel.
Surgical Castration
An anesthetized and surgically prepared animal was placed in dorsal recumbency. Both testes were then pushed down into the scrotal sacs by gently applying pressure to the abdomen. A 1-to 2-cm ventral midline incision was made in the scrotum and the skin was retracted to expose the tunica. The tunica was pierced and the testes were pushed out one at a time. The testes were then raised to expose the underlying blood vessels and tubules. The fat pad, which adheres to testis, was then grasped with blunt forceps to locate the vas deferens with the prominent blood vessel running along it. The testis was dissected away from the fat pad and removed. The fat pad was then pushed back into the scrotal sac. All deferential vessels and ducts were replaced back into the tunica. Skin incisions were closed with stainless steel wound closures and removed 7 to 10 days after operation.
Bioluminescence Imaging
In vitro , in vivo , and ex vivo bioluminescence imaging was performed using an Xenogen IVIS Spectrum imager, which uses a highly sensitive, cooled CCD camera mounted in a light-tight camera box.
For in vitro imaging, mouse embryonic fi broblasts (MEF) (1 × 10
The measured signal was quantifi ed as photons per second (ph/s) using the Living Image software v.4.2 (Xenogen). Background bioluminescence in vivo was in the range of 3 to 6 × 10 4 ph/s. For ex vivo imaging, animals were humanely euthanized, and tissues of interest were excised, placed individually on paraffi n fi lm, and imaged for 3 minutes after 3 mg of D -luciferin (200 μL of 15 mg/ mL in PBS) was dropped in each organ. Tissues were subsequently fi xed in 10% neutral-buffered formalin (Sigma) overnight and prepared for standard histopathologic evaluation. For JQ1 treatment trials, JQ1 stock (100 mg/mL) in dimethyl sulfoxide (DMSO) was diluted by the dropwise addition of a 10% 2-hydroxypropyl-β-cyclodextrin carrier (Sigma) under vortexing, resulting in a 5 mg/mL fi nal solution. Mice were intraperitoneally injected daily with freshly diluted JQ1 (50 mg/kg) or the same volume of carrier containing 5% DMSO. 
PCR Analysis to Confi rm Injection
Histology and IHC
Tissues were fi xed in 10% buffered formalin for 24 hours, followed by gentle wash and transfer to PBS. Tissues were fi xed in 10% buffered formalin for 24 hours, followed by gentle wash and transfer to PBS. Then, paraffi n-embedded tissues were sectioned 6 μm thick, placed on charged glass slides, and stained with H&E, or the appropriate immunohistochemical stains. Antigen retrieval was performed by incubating the slides in 0.01 mol/L citric acid buffer (pH 6.0) at 95°C for 15 minutes. Slides were then allowed to cool to room temperature for 20 minutes in a citric acid buffer. After the slides were washed with deionized water, they were transferred to TBS (pH 7.4) for 5 minutes. The following detection and visualization procedures were performed according to the manufacturer's protocol. Slides were counterstained in Mayer's hematoxylin, dehydrated, cleared, and cover-slipped. Negative control slides were run without primary antibody. Control slides known to be positive for each antibody were incorporated. For AR (D6F11, 1:500; Cell Signaling Technology), Ck8 (EP1628Y, 1:250; Novus Biologicals), cytokeratin 5 (CK5; AF138, 1:4,000; Covance), luciferase (NB100-1677, 1:500; Novus Biologicals), pAKT(Ser473) (D9E, 1:50; Cell Signaling Technology), pAKT(Thr308) (9275, 1:100; Cell Signaling Technology), PTEN (138G6, 1:50; Cell Signaling Technology), Pan-CK (sc-15367, 1:1,000; Santa Cruz Biotechnology), Ki-67 (VP-K452, 1:2,000; Vector Laboratories), pS6 Ser235/236 (4856, 1:200; Cell Signaling Technology), Nkx3.1(1:6,000; a kind gift from Dr. Chuck Bieberich, University of Maryland, Baltimore County), cMyc (1472-1, 1:50; Epitomics), GFP (ab290, 1:500; Abcam), and CD3 (ab5690, 1:1,000; Abcam) antibodies were used, using the Discovery XT Processor System (Ventana Medical Systems) as previously described ( 21 ) , or sections were fi rst blocked with 5% normal horse serum and 1% bovine serum albumin (in TBS) for 1 hour at room temperature, and then the primary antibodies were diluted, as suggested by the manufacturer, and incubated overnight at 4°C. Following three 10-minute washes with TBS, sections were incubated with biotinylated secondary antibody for 30 minutes at room temperature and rinsed with TBS three times for 10 minutes. Finally, the sections were treated with diaminobenzidine for 3 minutes and rinsed with distilled water to end the reaction, mounted on gelatin-coated slides, air-dried, dehydrated with 70% to 100% alcohol, cleared with xylene, and cover-slipped for microscopic observation. After examination of all immunohistochemical and special stains, stained slides were digitally scanned using the Aperio ScanScope software. Double immunofl uorescence staining was done with rabbit monoclonal Ck8 (EP1628Y, 1:250; Novus Biologicals) and mouse monoclonal PTEN antibody (138G6, 1:50; Cell Signaling Technology), followed by incubation with Alexa Fluor 488 donkey anti-rabbit (1:500; Life Technologies) and Alexa Fluor 546 goat anti-mouse (1:500; Life Technologies) antibodies for 1 hour at room temperature for visualization. To stain cell nuclei, sections were incubated with a 10 μg/mL solution of 4′,6-diamidino-2-phenylindole (DAPI) for 1 hour at room temperature. Sections were rinsed in TBS and distilled water serially, and fi nally mounted with Mounting Medium (H-1000; Vector Laboratories). Stained slides were imaged and analyzed using both the Ultraview VoX Spinning disk confocal microscope (PerkinElmer) and the Aperio ScanScope software.
Western Blot Analysis
Fresh-frozen tissues were lysed with radioimmunoprecipitation assay (RIPA) buffer [50 mmol/L NaCl; 1.0% IGEPAL CA-630; 0.5% sodium deoxycholate; 0.1% SDS, 50 mmol/L Tris, pH 8.0; 10 μg/ mL aprotinin; 1 mmol/L phenylmethylsulfonylfl uoride (PMSF); 1 mmol/L Na 2 VO 4 ; 10 μg/mL pepstatin, and 10 μg/mL leupeptin]. Tissue lysates were separated by electrophoresis in SDS-PAGE and transferred to nitrocellulose membranes. After blocking, membranes were hybridized with primary antibodies. Subsequently, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies and signals were detected with enhanced chemiluminescence. The following antibodies were used: anti-pPDK1 Ser241 (Cell Signaling Technology; #3061), anti-PDK1 (Cell Signaling Technology; #3062), anti-pS6 Ser235/236 (Cell Signaling Technology; #4856), anti-S6 (Cell Signaling Technology; #2217), and β-actin-HRP (Sigma; #A3854).
RNA Extraction and qRT-PCR
Total RNA was extracted from prostate or lymph node tissues using the TRizol reagent (Life Technologies) according to the manufacturer's instructions. RNA (2 μg) was used for fi rst-strand synthesis and cDNA produced using random primers and SuperScript II (Invitrogen). RNA expression was measured by real-time qRT-PCR, using the Roche LightCycler 480 (Roche Applied Science) based on the SYBR Green method. Each assay was done in triplicate and the expression of each gene was calculated relative to expression of β-actin cDNA. Quantifi cation was based on a standard curve obtained by serial dilution of the indicated control reverse transcription reaction.
DNA FISH
To detect cMyc, the probe was made using a nick-translated kit (Abbot Molecular; 07J00-001) as per the manufacturer's protocol. The paraffi n-embedded tissue sections were treated with 5% pepsin for 20 minutes at 37°C after deparaffi nization. Tissues were permeabilized with 0.5% TX-100/PBST for 5 minutes and RNase A was added for 1 hour at room temperature. For hybridization, cellular DNA was denatured in 70% deionized formamide/2× saline-sodium citrate (SSC) for 7 minutes at 80°C. Hybridization of oligo probes was performed in 50% deionized formamide, 10% dextran sulfate, 2× SSC , yeast tRNA, salmon sperm DNA, mouse Cot I DNA, and 50 ng nick-translated probe in a humidifi ed chamber overnight at 37°C. Tissues were washed with 50% deionized formamide/2× SSC at 37°C and then 15 minutes in 2× SSC and 1× SSC, respectively. Tissues were mounted and images obtained using a PerkinElmer Spinning Disk Confocal Microscope. For quantifi cation, the percentage of cells with Myc copies >2 was counted for more between 200 and 300 nuclei per tissue. 
